Bioceres Crop Solutions (BIOX) Q3 2025 earnings summary

Executive summary

• Fiscal Q3 is typically off-season, with this year notable for a $40.7 million year-over-year improvement in cash flow, aiding debt reduction and cash position enhancement.

• Revenues for Q3 were $60.6 million, down 28% year-over-year, mainly due to the absence of a $15.7 million Syngenta downpayment accrued last year.

• Adjusted EBITDA was $9.0 million, a 57% decrease year-over-year, reflecting lower gross profit and the absence of the Syngenta payment.

• EPA approval of Rinotec enables a full suite of biological solutions for pest control and plant health, with regulatory approvals in the US and Brazil.

• Strategic shift in the seed business and operational focus contributed to improved cash flow and working capital efficiency.

Financial highlights

• Q3 revenues were $60.6 million, down from $84 million year-over-year, mainly due to the absence of the Syngenta down payment.

• Gross profit was $23.8 million, down from $42.6 million, with gross margin declining from 51% to 39% due to the prior year’s one-time Syngenta payment.

• Adjusted EBITDA was $9.0 million, compared to $21.1 million last year, mainly due to the Syngenta payment impact.

• Net loss for the period was $1.6 million, compared to a profit of $9.8 million in 3Q24.

• Net cash from operating activities was $23.3 million, a $40.7 million improvement year-over-year, driven by inventory reduction and improved receivables.

Outlook and guidance

• Additional $10 million in working capital improvement expected as the HB4 transition completes.

• Targeting a return to historical working capital levels and EBITDA margins around 25% as industry normalizes.

• Strategic focus on expanding platform presence in Brazil, US, Mexico, and the EU, leveraging innovation from technology platforms for FY26-28.

• Market introduction of Rinotec platform in the US and Brazil expected to begin in FY26, supported by regulatory approvals and partnerships.

• Management expects further benefits from cost structure realignment and seed business reorganization in coming quarters.